Neurona Therapeutics Stock

www.neuronatherapeutics.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $240.58MM

Neurona Therapeutics is a company that strives to develop clinical-stage biotherapeutic treatments for neurological disorders with a focus on advancing regenerative cell therapy candidates. The company researches allogeneic therapies that come from stem cells harvested from donors. Neurona's proprietary therapy NRTX-1001 aims to reverse the effects of Alzheimer’s disease and other nervous system disorders. Neurona Therapeutics was founded by Arnold Kriegstein and Cory R. Nicholasin in 2008 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Neurona Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Neurona Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Neurona Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Neurona Therapeutics investors also invested in these private companies

Ironfire Ventures
UC Investments
LYFE Capital
Schroders Capital
UCB Ventures
California Institute for Regenerative Medicine
Topspin Consumer Partners
Sphera Funds Management
Harvard University Endowment
Berkeley Frontier Fund

Team

Management Team

Cory Nicholas Ph.D
Co-Founder & Chief Executive Officer
Arturo Álvarez-Buylla Ph.D
Co-Founder & Scientific Advisor
John Rubenstein Ph.D
Co-Founder & Scientific Advisor
Arnold Kriegstein Ph.D
Co-Founder & Scientific Advisor
James Stutz
Chief Financial Officer & Chief Business Officer
Gautam Banik Ph.D
Chief Technology Officer
Catherine Priest Ph.D
Chief Development Officer
David Blum MD
Chief Medical Officer

Board Members

David Goeddel Ph.D
The Column Group
Erica Whittaker Ph.D
UCB Ventures
Raymond Kelleher Ph.D
Cormorant Asset Management
Robert Tjian Ph.D
The Column Group
Timothy Kutzkey Ph.D
The Column Group

Neurona Therapeutics stock FAQs

plusminus

Can you buy Neurona Therapeutics stock?

As Neurona Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Neurona Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy Neurona Therapeutics stock?

To invest in a private company like Neurona Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Neurona Therapeutics stock?

Yes, you may be able to sell your Neurona Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Neurona Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Neurona Therapeutics stock on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is Neurona Therapeutics a public company?

No, Neurona Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Neurona Therapeutics’ stock price?

Neurona Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Neurona Therapeutics’ private market stock price with Forge Data.
plusminus

What is Neurona Therapeutics’ stock ticker symbol?

Neurona Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Neurona Therapeutics on Thursday announced that it has secured $120 million in funding, which will help it advance its pipeline of investigational off-the-shelf cell therapies. The California-based biotech will use the money to advance its lead candidate NRTX-1001, a regenerative neural cell therapy candidate being assessed in a Phase I/II trial for drug-resistant mesial temporal lobe epilepsy (MTLE), the most common form of focal epilepsy that can trigger ongoing seizures despite medical treatment.
Neurona Therapeutics, a San Francisco, CA-based clinical-stage biotherapeutics company, raised $120M in funding
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.